美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

BlossomHill Therapeutics

16.38

+0.58003.67%

盤後：16.380.00000.00%19:30 EDT

成交量：11.14萬

成交額：180.68萬

市值：5.02億

市盈率：-6.70

高：16.50

開：16.00

低：15.75

收：15.80

52周最高：17.25

52周最低：15.25

股本：3,064.37萬

流通股本：937.50萬

量比：0.45

換手率：1.19%

股息：- -

股息率：- -

每股收益(TTM):-2.4440

每股收益(LYR):-24.8342

淨資產收益率：--

總資產收益率：--

市淨率：-3.30

市盈率(LYR):-0.66

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

BlossomHill Therapeutics

交易所：

NASDAQ

成立時間：

2020

員工人數：

- -

公司地址：

10255 Science Center Drive,Suite 200,San Diego,California,United States

官網：

http://www.bhtherapeutics.com

郵編：

92121

電話：

傳真：

- -

簡介：

BlossomHill Therapeutics, Inc.於2020年6月22日在特拉華州註冊成立。該公司是一家臨床階段的生物製藥公司，應用基於化學的合理藥物設計方法來開發創新的小分子藥物，以解決癌症治療中未滿足的重大醫療需求。其科學創始人和團隊在開發創新小分子藥物方面有着良好的記錄，這些藥物克服了現有療法的局限性，包括多種獲得批準的療法，這些療法已經帶來了轉化的患者結果。

董事

名稱

職位

J. Jean Cui

Chief Executive Officer and Director and President

Y. Peter Li

Executive Chairman and Director

Bihua Chen

Director

Carl L. Gordon

Director

John Schmid

Director

Sheila Gujrathi

Director

Sundeep Agrawal

Director

Timothy Stubbs

Director

股東

名稱

職位

J. Jean Cui

Chief Executive Officer and Director and President

Jason Keyes

Chief Financial Officer and Executive Vice President

Geoff Oxnard

Chief Medical Officer and Executive Vice President

Vincent Liptak

Executive Vice President and General Counsel

Y. Peter Li

Executive Chairman and Director

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/BLSM/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BLSM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BLSM\",,,,,undefined,":{"symbol":"BLSM","market":"US","secType":"STK","nameCN":"BlossomHill Therapeutics","latestPrice":16.38,"timestamp":1787342400000,"preClose":15.8,"halted":0,"volume":111393,"hourTrading":{"tag":"盘后","latestPrice":16.38,"preClose":16.38,"latestTime":"19:30 EDT","volume":19,"amount":307.42,"timestamp":1787355008098,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.03670886075949356,"floatShares":9375000,"shares":30643700,"eps":-2.444,"marketStatus":"休市中","change":0.58,"latestTime":"08-21 16:00:00 EDT","open":16,"high":16.5,"low":15.75,"amount":1806784.4346299998,"amplitude":0.047468,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.444,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1786075200000,"exchange":"NASDAQ","adjPreClose":15.8,"postHourTrading":{"tag":"盘后","latestPrice":16.38,"preClose":16.38,"latestTime":"19:30 EDT","volume":19,"amount":307.42,"timestamp":1787355008098,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.4536184656458545},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BLSM\",,,,,undefined,":{"symbol":"BLSM","floatShares":9375000,"roa":"--","roe":"--","lyrEps":-24.834182,"volumeRatio":0.4536184656458545,"shares":30643700,"dividePrice":0,"high":16.5,"amplitude":0.047468,"preClose":15.8,"low":15.75,"week52Low":15.25,"pbRate":"-3.30","week52High":17.2488,"institutionHeld":0,"latestPrice":16.38,"eps":-2.444,"divideRate":0,"volume":111393,"delay":0,"ttmEps":-2.444,"open":16,"prevYearClose":16,"prevWeekClose":16.18,"prevMonthClose":16,"prevQuarterClose":16,"fiveDayClose":16.18,"twentyDayClose":16,"sixtyDayClose":16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BLSM\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BLSM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BLSM\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BLSM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BLSM","date":"2026-08-21","current":-6.702128,"percent":0.909091,"low":-7.12152,"twenty":-7.038752,"median":-6.955553,"eighty":-6.893907,"high":-2.788792,"avg":-6.617124,"sd":1.157195,"marketCap":484169828},"quantilePoints":[{"date":"2026-08-07","current":-6.897356,"twenty":-6.075643,"median":-4.843074,"eighty":-3.610505,"marketCap":490298560},{"date":"2026-08-14","current":-7.048236,"twenty":-7.038752,"median":-6.897356,"eighty":-6.893907,"marketCap":501023841},{"date":"2026-08-21","current":-6.811139,"twenty":-7.038752,"median":-6.955553,"eighty":-6.893907,"marketCap":484169828}],"updateTime":1787522420165},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":700852009,"yearFounded":2020,"address":"10255 Science Center Drive,Suite 200,San Diego,California,United States","zipCode":"92121","officePhone":"(858) 732-3880","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"websiteUrl":"http://www.bhtherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0124},{"period":"1month","weight":0.0237},{"period":"ytd","weight":0.0237}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.1107},{"period":"1year","weight":0.2048},{"period":"ytd","weight":0.1229}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"BlossomHill Therapeutics, Inc.於2020年6月22日在特拉華州註冊成立。該公司是一家臨床階段的生物製藥公司，應用基於化學的合理藥物設計方法來開發創新的小分子藥物，以解決癌症治療中未滿足的重大醫療需求。其科學創始人和團隊在開發創新小分子藥物方面有着良好的記錄，這些藥物克服了現有療法的局限性，包括多種獲得批準的療法，這些療法已經帶來了轉化的患者結果。","exchange":"NASDAQ","name":"BlossomHill Therapeutics","nameEN":"BlossomHill Therapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"BLSM\",market:\"US\",,,undefined,":{"directors":[{"name":"J. Jean Cui","position":"Chief Executive Officer and Director and President"},{"name":"Y. Peter Li","position":"Executive Chairman and Director"},{"name":"Bihua Chen","position":"Director"},{"name":"Carl L. Gordon","position":"Director"},{"name":"John Schmid","position":"Director"},{"name":"Sheila Gujrathi","position":"Director"},{"name":"Sundeep Agrawal","position":"Director"},{"name":"Timothy Stubbs","position":"Director"}],"executives":[{"name":"J. Jean Cui","position":"Chief Executive Officer and Director and President"},{"name":"Jason Keyes","position":"Chief Financial Officer and Executive Vice President"},{"name":"Geoff Oxnard","position":"Chief Medical Officer and Executive Vice President"},{"name":"Vincent Liptak","position":"Executive Vice President and General Counsel"},{"name":"Y. Peter Li","position":"Executive Chairman and Director"}]}}}